TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27936083

Group type: EXPERIMENTAL
Intervention: Individual counseling on physical activity and diet and weight gain at five antenatal visits
Number of subjects: 173
Study: 24610683

Group type: COMPARATOR
Intervention: InsuPatch device on day 1
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: InsuPatch device on day 3
Number of subjects: 56
Study: 22613740

Group type: EXPERIMENTAL
Intervention: Head-down bed rest (HDBR) for 24 hours
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Diuretic treatment (spironolactone, 100 mg day(-1) for 3 days)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Lower body negative pressure treatments (LBNP, -15 and -35 mmHg)
Number of subjects: 17
Study: 20553617

Group type: EXPERIMENTAL
Intervention: Group-based fatigue management intervention (6 sessions)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Current local practice
Number of subjects: 180
Study: 18350270

Group type: EXPERIMENTAL
Intervention: Heliox21 (79% helium) via a standard non-rebreathe reservoir mask
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Heliox via a tightly fitting cushioned facemask
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Normal breathing of Heliox21
Number of subjects: 6
Study: 16035709

Group type: EXPERIMENTAL
Intervention: Burst TENS stimulation
Number of subjects: 18

Group type: COMPARATOR
Intervention: No stimulus (Control)
Number of subjects: 18
Study: 11895532

Group type: EXPERIMENTAL
Intervention: Massage intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no massage)
Number of subjects: 60
Study: 10047626

Group type: EXPERIMENTAL
Intervention: 10 mg of lovastatin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10 mg of pravastatin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both agents
Number of subjects: 30
Study: 7744265

Group type: EXPERIMENTAL
Intervention: AZT therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No AZT therapy
Number of subjects: 0
Study: 2116690

Group type: EXPERIMENTAL
Intervention: Cyclosporine (10 mg/kg) daily during donor-specific transfusion (DST)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no cyclosporine)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cyclosporine (10 mg/kg) during DST
Number of subjects: 80
Study: 6451351

Group type: EXPERIMENTAL
Intervention: DepoProvera 25mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: DepoProvera 50mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: DepoProvera 100mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: DepoProvera 150mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: DepoProvera 100mg and 150mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: DepoProvera (all doses)
Number of subjects: 4
Study: 31064089

Group type: EXPERIMENTAL
Intervention: Extreme Weather Events (EWE)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Adaptation Measures
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Cold Spells
Number of subjects: 350
Study: 28780595

Group type: EXPERIMENTAL
Intervention: Vapocoolant spray (Group V)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lidocaine (Group L)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 90
Study: 26202595

Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ) plus veliparib 20 mg
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ) plus veliparib 40 mg
Number of subjects: 346

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 346
Study: 23066973

Group type: EXPERIMENTAL
Intervention: PPA904 (active treatment)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 32
Study: 21287313

Group type: EXPERIMENTAL
Intervention: Equal reinforcement, no-limited-hold condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Equal reinforcement condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased number of baseline training trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response speed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response accuracy
Number of subjects: 0
Study: 19626470

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy with ABCB1 polymorphism
Number of subjects: 48

Group type: COMPARATOR
Intervention: Corticosteroid therapy without ABCB1 polymorphism (Control group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 48
Study: 17094818

Group type: EXPERIMENTAL
Intervention: Individual problem-solving treatment
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Group psychoeducation
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 236
Study: 15593198

Group type: EXPERIMENTAL
Intervention: 20 mug/day teriparatide
Number of subjects: 444

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 444
Study: 11348716

Group type: EXPERIMENTAL
Intervention: Influenza vaccine (administered to hospitalized patients)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Influenza vaccine (administered to ambulatory clinic patients)
Number of subjects: 228
Study: 9562516

Group type: EXPERIMENTAL
Intervention: Neutralizing anti-TNF-alpha monoclonal antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant IL-10
Number of subjects: 0
Study: 8102720

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 11124
Study: 2890670

Group type: EXPERIMENTAL
Intervention: Quazepam 15 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Quazepam 30 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Pentobarbital 150 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 30470764

Group type: EXPERIMENTAL
Intervention: HIV positive individuals not on antiretroviral treatment (ART)
Number of subjects: 5059

Group type: COMPARATOR
Intervention: HIV negative individuals
Number of subjects: 5059

Group type: COMPARATOR
Intervention: Individuals on ART
Number of subjects: 5059
Study: 29903135

Group type: EXPERIMENTAL
Intervention: Whole milk supplemented with inulin (150 mg/100 g), vitamin D3 (2.0 μg/100 g), casein phosphopeptides (5.0 mg/100 mL), milk minerals (40 mg/100 g)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low-lactose whole milk
Number of subjects: 42
Study: 25558641

Group type: EXPERIMENTAL
Intervention: Whole-body vibration treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no whole-body vibration)
Number of subjects: 16
Study: 22218671

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 592

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 592
Study: 20837852

Group type: EXPERIMENTAL
Intervention: Immune globulin intravenous, 10% caprylate‐chromatography purified (2 g/kg loading dose, 1 g/kg maintenance every 3 weeks)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo (loading dose and maintenance every 3 weeks)
Number of subjects: 117
Study: 18793067

Group type: EXPERIMENTAL
Intervention: PALS I intervention during infancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PALS II intervention during toddler-preschool phase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Developmental Assessment Sessions condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PALS I and PALS II interventions across both periods
Number of subjects: 0
Study: 16324142

Group type: COMPARATOR
Intervention: Clearfil SE non-etch
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Clearfil SE etch
Number of subjects: 29
Study: 14569932

Group type: EXPERIMENTAL
Intervention: Self-examination education program
Number of subjects: 123748

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123748
Study: 10425464

Group type: EXPERIMENTAL
Intervention: GH (0.3 IU/kg per day s.c.) and IGF-I (80 microgram/kg per day s.c.)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: GH (0.3 IU/kg per day s.c.)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: GH and IGF-I
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (saline s.c.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Methylprednisolone alone
Number of subjects: 24
Study: 7491395

Group type: EXPERIMENTAL
Intervention: Lithium 600 mg loading dose
Number of subjects: 16
Study: 1822317

Group type: EXPERIMENTAL
Intervention: Aniracetam (Ro 13-5057)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 7035480

Group type: EXPERIMENTAL
Intervention: Oral prophylactic urea treatment (low doses)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 79
Study: 31887743

Group type: EXPERIMENTAL
Intervention: MIV‐711, 100 mg daily
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: MIV‐711, 200 mg daily
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: MIV‐711 (both dosages)
Number of subjects: 244
Study: 29944510

Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1% drops
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketorolac 0.5% ophthalmic drops
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no NSAID applied until the third day)
Number of subjects: 60
Study: 27922719

Group type: EXPERIMENTAL
Intervention: Oral tenofovir disoproxil fumarate (TDF)
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: TDF in combination with emtricitabine (FTC)
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1147
Study: 25613986

Group type: EXPERIMENTAL
Intervention: Familiar Auditory Sensory Training (FAST)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo of silence
Number of subjects: 15
Study: 24372182

Group type: EXPERIMENTAL
Intervention: Herbal medicines
Number of subjects: 400
Study: 23136538

Group type: EXPERIMENTAL
Intervention: Multiple-dose parecoxib (40mg at 30min before the end of surgery, at 8 and 20hr after surgery)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Single-dose parecoxib (40mg at 30min before the end of surgery)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control (normal saline at the same three time points)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Multiple-dose parecoxib
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 126
Study: 19406258

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 4157

Group type: COMPARATOR
Intervention: Heparin + GPI
Number of subjects: 4157

Group type: COMPARATOR
Intervention: Men
Number of subjects: 4157

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 4157
Study: 17388667

Group type: EXPERIMENTAL
Intervention: Low plasma 25(OH)D levels and the less functional FokI ff genotype
Number of subjects: 14116

Group type: EXPERIMENTAL
Intervention: High plasma 25(OH)D levels (above median)
Number of subjects: 14116

Group type: EXPERIMENTAL
Intervention: Both 25(OH)D and 1,25(OH)D levels below the median
Number of subjects: 14116

Group type: COMPARATOR
Intervention: Plasma 25(OH)D levels above the median with FokI FF or Ff genotype
Number of subjects: 14116
Study: 15457579

Group type: EXPERIMENTAL
Intervention: HBIG (200 IU intramuscularly every 4 weeks from 28 weeks of gestation to delivery)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control (no special treatment)
Number of subjects: 112
Study: 11800450

Group type: EXPERIMENTAL
Intervention: Confirmation call made one working day before appointment
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Confirmation call made two working days before appointment
Number of subjects: 313

Group type: COMPARATOR
Intervention: Control group (no confirmation call)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Overall confirmation calls (both groups)
Number of subjects: 313
Study: 9547681

Group type: EXPERIMENTAL
Intervention: ACE unit intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 8284765

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO)
Number of subjects: 0
Study: 3338362

Group type: EXPERIMENTAL
Intervention: Placebo therapy prior to the meal
Number of subjects: 20

Group type: COMPARATOR
Intervention: No placebo therapy prior to the meal
Number of subjects: 20
Study: 4948415

Group type: EXPERIMENTAL
Intervention: Oral killed typhoid vaccine (3 tablets containing 100x10(9) killed Salmonella typhi)
Number of subjects: 13374

Group type: COMPARATOR
Intervention: Placebo (3 tablets)
Number of subjects: 13374
Study: 31567041

Group type: COMPARATOR
Intervention: Cash incentive of 5 Nigerian naira (C5)
Number of subjects: 2482

Group type: EXPERIMENTAL
Intervention: Cash incentive of 300 Nigerian naira (C300)
Number of subjects: 2482

Group type: EXPERIMENTAL
Intervention: Cash incentive of 800 Nigerian naira (C800)
Number of subjects: 2482
Study: 30595283

Group type: COMPARATOR
Intervention: Prasugrel 60 mg loading dose (group A)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Prasugrel 30 mg loading dose (group B)
Number of subjects: 332
Study: 27387557

Group type: EXPERIMENTAL
Intervention: Kinesiophobia measured with the Tampa Scale of Kinesiophobia (TSK-11) at baseline and 12-month follow-up.
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Associations of demographic, cognitive affective, and pain-related variables to kinesiophobia.
Number of subjects: 433
Study: 24772585

Group type: EXPERIMENTAL
Intervention: Generic SFC
Number of subjects: 51

Group type: COMPARATOR
Intervention: Original SFC
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 51
Study: 22865477

Group type: EXPERIMENTAL
Intervention: Leukocyte depletion (LD)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard arterial filters (Controls)
Number of subjects: 70
Study: 20861205

Group type: EXPERIMENTAL
Intervention: Higher pump flow (20% more than the usual flow during hypothermia)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal flow
Number of subjects: 12
Study: 18664040

Group type: EXPERIMENTAL
Intervention: Fundamental movement skills (FMS) proficiency
Number of subjects: 248

Group type: COMPARATOR
Intervention: Weight status
Number of subjects: 248
Study: 16846322

Group type: EXPERIMENTAL
Intervention: Intervention (8 churches)
Number of subjects: 755

Group type: COMPARATOR
Intervention: Control (6 churches)
Number of subjects: 755
Study: 12654359

Group type: EXPERIMENTAL
Intervention: Azithromycin (1-g single dose)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg twice daily for 10 days)
Number of subjects: 78
Study: 10037363

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy (ESWL) with 1,800 to 3,200 shock waves
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pyelolithotomy
Number of subjects: 60
Study: 8560677

Group type: EXPERIMENTAL
Intervention: Bicalutamide (50 mg/day)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Castration
Number of subjects: 1000
Study: 1881993

Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 0
Study: 7105391

Group type: EXPERIMENTAL
Intervention: Beclomethasone diproprionate
Number of subjects: 67

Group type: COMPARATOR
Intervention: Flunisolide
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Positive cultures pre-trial
Number of subjects: 67

Group type: COMPARATOR
Intervention: Negative cultures pre-trial
Number of subjects: 67
Study: 31707978

Group type: EXPERIMENTAL
Intervention: Advanced practice physiotherapists (APP)
Number of subjects: 113
Study: 30389760

Group type: EXPERIMENTAL
Intervention: Intraoperative cell salvage (ICS) reinfusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Donor blood transfusion
Number of subjects: 60
Study: 26772736

Group type: EXPERIMENTAL
Intervention: Blumgart pancreatic anastomosis
Number of subjects: 253

Group type: COMPARATOR
Intervention: Cattell-Warren pancreatic anastomosis
Number of subjects: 253
Study: 25088807

Group type: EXPERIMENTAL
Intervention: Group A (individual and family education, FOBT kits provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group B (individual education only, FOBT kits provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group C (no education, FOBT kits provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group D (no education or FOBT kits provided)
Number of subjects: 0
Study: 22285316

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation 2.4 g/day (1,400 mg eicosapentaenoic acid + 1,000 mg docosahexaenoic acid)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (safflower oil)
Number of subjects: 31
Study: 20201654

Group type: EXPERIMENTAL
Intervention: Plasma disc decompression (PDD)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Fluoroscopy-guided transforaminal epidural steroid injection (TFESI)
Number of subjects: 90
Study: 17224456

Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 85
Study: 16050885

Group type: EXPERIMENTAL
Intervention: OCP encounter cards rating nine presentation competencies
Number of subjects: 164

Group type: COMPARATOR
Intervention: Usual feedback
Number of subjects: 164
Study: 11952483

Group type: EXPERIMENTAL
Intervention: Ocuton S tonometer
Number of subjects: 80

Group type: COMPARATOR
Intervention: Goldmann tonometer
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Self-tonometry
Number of subjects: 80
Study: 9854199

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography followed by endoscopic retrograde cholangiography and sphincterotomy
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 125
Study: 7876610

Group type: EXPERIMENTAL
Intervention: One, two, or three doses of group A plus group C meningococcal polysaccharide‐CRM197 conjugate vaccine
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: One dose of conjugate vaccine at 6 months
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Two doses of conjugate vaccine
Number of subjects: 304

Group type: COMPARATOR
Intervention: Two doses of meningococcal A plus C polysaccharide vaccine
Number of subjects: 304
Study: 2171850

Group type: EXPERIMENTAL
Intervention: Cold stimulus applied to the exterior of the left cheek
Number of subjects: 12

Group type: COMPARATOR
Intervention: Room temperature challenge
Number of subjects: 12
Study: 342886

Group type: EXPERIMENTAL
Intervention: Fluphenazine dekanoate (Dapotum D minor)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 30594892

Group type: EXPERIMENTAL
Intervention: Single-set resistance training (RT) program, 12 weeks, 3 times per week, 10-15 repetitions in 8 exercises
Number of subjects: 48
Study: 29231146

Group type: EXPERIMENTAL
Intervention: Tintinalli regimen (naloxone 0.1 mg every 2-3 minutes)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Goldfrank regimen (naloxone starting at 0.04 mg, increasing to 0.4, 2, and 10 mg every 2-3 minutes)
Number of subjects: 100
Study: 25796267

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 23174253

Group type: EXPERIMENTAL
Intervention: Laparoendoscopic single site varicocele ligation with preservation of the testicular artery and lymphatics (Group 1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Complete ligation of the testicular vessels and lymphatics (Group 2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patients with subfertility in Group 1
Number of subjects: 80

Group type: COMPARATOR
Intervention: Patients with subfertility in Group 2
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patients with scrotal pain in Group 1
Number of subjects: 80

Group type: COMPARATOR
Intervention: Patients with scrotal pain in Group 2
Number of subjects: 80
Study: 20346089

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg for 14 days)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg for 14 days)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combined treatment (Amlodipine followed by Lisinopril)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 25
Study: 19423854

Group type: EXPERIMENTAL
Intervention: Fluid management guided by daily measurements of blood volume (BV)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional fluid balance guided fluid therapy
Number of subjects: 102
Study: 16442481

Group type: EXPERIMENTAL
Intervention: Morphine (2.5 mg every 4 hours) with midazolam rescue doses (5 mg) for breakthrough dyspnea (Group Mo)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Midazolam (5 mg every 4 hours) with morphine rescue doses (2.5 mg) for breakthrough dyspnea (Group Mi)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Morphine (2.5 mg every 4 hours) plus midazolam (5 mg every 4 hours) with morphine rescue doses (2.5 mg) for breakthrough dyspnea (Group MM)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as standard morphine treatment without midazolam)
Number of subjects: 101
Study: 14703543

Group type: EXPERIMENTAL
Intervention: Volunteer support from counsellors for breast feeding
Number of subjects: 720

Group type: COMPARATOR
Intervention: Control group (no volunteer support)
Number of subjects: 720
Study: 11359587

Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil (PR)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propofol (P)
Number of subjects: 80
Study: 9256868

Group type: EXPERIMENTAL
Intervention: Physical therapy for 1 month
Number of subjects: 66

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 66
Study: 8269574

Group type: EXPERIMENTAL
Intervention: Fresh gas flow rates of 5.7 L.min‐1
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Fresh gas flow rates of 8.0 L.min‐1
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Fresh gas flow rates of 9.3 L.min‐1
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Fresh gas flow rates of 10.4 L.min‐1
Number of subjects: 37
Study: 3739696

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (Ppa)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 29435828

Group type: EXPERIMENTAL
Intervention: Combination or bridging therapy (C/BT)
Number of subjects: 188
Study: 26538582

Group type: EXPERIMENTAL
Intervention: Walking pace >3 mph
Number of subjects: 4207

Group type: COMPARATOR
Intervention: Walking pace <2 mph
Number of subjects: 4207
Study: 25816544

Group type: EXPERIMENTAL
Intervention: Posterior pericardiotomy (PP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no posterior pericardiotomy)
Number of subjects: 20